Publications by authors named "Sergio Enrique Juan Belloc"
Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study.
Guillermo Ezpeleta Ana Navascués Natividad Viguria Mercedes Herranz-Aguirre Sergio Enrique Juan Belloc
Vaccines (Basel)
April 2024
Article Synopsis
- Respiratory syncytial virus (RSV) is a common cause of hospitalization in newborns, but the risk decreases with age, prompting the use of nirsevimab for prevention in infants during their first RSV season.
- A study conducted in Navarre, Spain, showed that nirsevimab significantly reduced RSV hospitalizations, with a 88.7% effectiveness rate in infants who received the immunization at birth compared to those who did not.
- Immunizing infants born between October and December 2023 was found to prevent one hospitalization for every 15.3 infants immunized, suggesting that a strategy for immunization during RSV seasons could greatly reduce pediatric hospital admissions.